Cholecystokinin receptor agonists block the jumping behaviour precipitated in morphine-dependent mice by naloxone

European Neuropsychopharmacology

Volumn 9, Issue 1-2, 1999, Pages 37-43

  Bourin, Michel ^a   Malinge, Myriam ^a   Colombel, Marie Claude ^a   Vasar, Eero ^b  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITY OF TARTU   (Estonia)

Author keywords

Acetorphan; CCK agonists; CCK antagonists; Precipitated jumping

Indexed keywords

ACETORPHAN; CERULETIDE; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; ENKEPHALIN; MORPHINE; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; NALOXONE; OPIATE; OPIATE ANTAGONIST; TETRAGASTRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DRUG MEGADOSE; INTRAPERITONEAL DRUG ADMINISTRATION; JUMPING; LOCOMOTION; MALE; MOUSE; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; CAERULEIN; DEVAZEPIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; HORMONE ANTAGONISTS; MALE; MICE; MORPHINE DEPENDENCE; MOTOR ACTIVITY; NALOXONE; NARCOTIC ANTAGONISTS; PYRAZOLES; RECEPTORS, CHOLECYSTOKININ; SUBSTANCE WITHDRAWAL SYNDROME; TETRAGASTRIN; THIORPHAN;

EID: 0032968834     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(97)00104-1     Document Type: Article

References (48)

1. Barbaz, B.S., Autry, W.L., Ambrose, F.G., Hall, N.R., Liebman, J.M., 1986. Antinociceptive profile of sulfated CCK-8: comparison with CCK-4, unsulfated CCK-8 and other neuropeptides. Neuropharmacology 25, 823-829.
2. Berthold, H., Borel, J.F., Flückiger, E., 1989. Enigmatic action of ciclosporine A on the naloxone-precipitated morphine withdrawal syndrome in mice. Neuroscience 31, 97-103.
3. Bianchetti, A., Giudice, A., Nava, F., Manara, L., 1986. Dissociation of morphine withdrawal diarrhea and jumping in mice by the peripherally selected opioid antagonist SR 58002C. Life Sci. 39, 2297-2303.
4. Bläsig, J., Herz, A., Reinhold, K., Zieglgänsberger, S., 1973. Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia 33, 19-38.
5. Boissier, J.R., Simon, P., 1965. Action de la caféine sur la motilité de la souris. Arch. Int. Pharmacodyn. 158, 212-221.
6. Cesselin, F., 1995. Opioid and anti-opioid peptides. Fundam. Clin. Pharmacol. 9, 409-433.
7. Collin, E., Cesselin, F., 1991. Neurobiological mechanisms of opioid tolerance and dependence. Clin. Neuropharmacol. 14, 465-488.
8. Derrien, M., Noble, F., Maldonado, R., Roques, B.P., 1993. Cholecystokinin A but not cholecystokinin B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci. Lett. 160, 193-196.
9. Ding, X.Z., Fan, S.G., Zhou, J.P., Han, J.S., 1986. Reversal of tolerance to morphine but not potentiation of morphine induced analgesia by antiserum against holecystokinin octapeptide. Neuropharmacology 25, 1155-1160.
10. B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur. J. Pharmacol. 176, 35-44.
11. Durieux, C., Charpentier, B., Pelaprat, D., Roques, B.P., 1986. Investigation on the metabolism of CCK-8 analogues by rat brain slices. Neuropeptides 7, 1-9.
12. 3H]pBC 264. Eur. J. Pharmacol. 209, 185-193.
13. Dzoljic, M.R., Rademaker, B., Van der Poel-Heisterkomp, A.L., Ukponmwan, O.E., Haffmans, J., 1986. Enkephalinase inhibition supprresser naloxone-induced jumping in morphine dependant mice. Arch. Int. Pharmacol. Ther. 28, 222-228.
14. Gall, C., Lauterborn, J., Burks, D., Seroogy, K., 1987. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain. Brain Res. 403, 403-408.
15. Haffmans, J., Dzoljic, M.C., 1987. Inhibition of enkephalinase activity attenuates naloxone-precipitated withdrawal symptoms. Gen. Pharmac. 18, 103-105.
16. Harro, J., Pöld, M., Vasar, E., 1990. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse; influence of acute and subchronic diazepam treatment. Naunyn-Schmiedeberg's Arch. Pharmacol. 341, 62-67.
17. Harro, J., Pöld, M., Vasar, E., Allikmets, L., 1989. The role of CCK-ergic mechanisms in the regulation of emotional behaviour in rodents. J. Higher Nerv. Activity 39, 877-883.
18. Hill, D.R., Singh, I., Boden, P., Pinnock, R., Woodruff, G.N., Hughes, J., 1992. Detection of CCK receptor subtypes in mammalian brain using highly selective non-peptide antagonists. In: Dourish, C.T., Cooper, S.J., Iversen, S.D., Iversen, I.I., (Eds.), Multiple Cholecystokinin Receptors in CNS. Oxford University Press, N.Y., pp. 57-76.
19. Hoffman, O., Wiesenfeld-Hallin, Z., 1994. The CCK-B receptor antagonist CI 988 reverses tolerance to morphine in rats. Neuroreport 5, 2565-2568.
20. Hollander, M., Wolfe, D.A., 1973. Nonparametric Statistical Methods. Wiley, New York.
21. Jacob, J.J.C., Barthelemy, C.D., Tremblay, E.C., Colombel, M.C., 1974. Potential usefulness of single-dose acute physical dependence on and tolerance to morphine for the evaluation of narcotic antagonists. In: Braude, M.C., Harris, L.S., May, E.L., Smith, J.P., Villarreal, J.E. (Eds.), Narcotic Antagonists. Advances In Biochemical Psychopharmacology, vol. 8. Raven Press, New-York, pp. 299-318.
22. Jurna, I., Zetler, G., 1981. Antinociceptive effect of centrally administered caerulein and cholecystokinin (CCK). Eur. J. Pharmacol. 73, 323-331.
23. Lecomte, J.M., Costentin, J., Vlaiculescu, A., et al., 1986. Pharmacological properties of acetorphan, a parenterally active "enkephalinase" inhibitor. J. Pharmacol. Exp. Ther. 237, 937-944.
24. Li, Y., Han, J.S., 1989. Cholecystokinin-octapeptide antagonizes morphine analgesia in periaqueductal gray of the rat. Brain Res. 480, 105-110.
25. Ling, G.S.F., Mac Leod, J.M., Lee, S., Lockhart, S.H., Pasternak, G.W., 1984. Separation of morphine analgesia from physical dependence. Science 226, 462-464.
26. Livingston, S.J., Sewell, R.D.E., Rooney, K.F., Smith, H.J., 1988. Amelioration of naloxone precipitated opioid withdrawal symptoms by peripheral administration of the enkephalinase inhibitor acetorphan. Psychopharmacology 94, 540-544.
27. Maldonado, R., Dauge, Y., Callebert, J., et al., 1989. Comparison of selective and complete inhibitors of enkephalin-degrading enzymes on morphine withdrawal syndrome. Eur. J. Pharmacol. 165, 199-207.
28. Maldonado, R., Stinus, L., Gold, L.H., Koob, G.F., 1992. Role of different brain structures in the expression of the physical morphine withdrawal syndrome. J. Pharmacol. Exp. Ther. 261, 669-677.
29. Maldonado, R., Valverde, O., Derrien, M., Tejedorreal, P., Roques, B.P., 1994. Effects induced by BC 264, a selective agonist of CCK-B receptors, on morphine-dependent rats. Pharmacol. Biochem. Behav. 48, 363-369.
30. B receptors in behavioural and hormonal studies in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 349, 478-484.
31. Moran, T.H., Robinson, P.H., Golrich, M.S., McHugh, P.R., 1986. Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res. 362, 175-179.
32. Nielsen, F.C., Rehfeld, J.F., 1995. Molecular forms and regional distribution of cholecystokinin in the central nervous system. In: Bradwejn, J., Vasar, E. (Eds.), Cholecystokinin and Anxiety; from Neuron to Behavior. Springler Verlag-R.G. Landes Company, Austin, pp. 33-56.
33. Noble, F., Derrien, M., Roques, B.P., 1993. Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br. J. Pharmacol. 109, 1064-1070.
34. Noble, F., Smadja, C., Roques, B.P., 1994. Role of endogenous cholecystokinin in the facilitation of mu-mediated antinociception by delta-opioid agonists. J. Pharmacol. Exp. Ther. 271, 1127-1134.
35. Ossipov, M.H., Kovelowski, C.J., Vanderah, T., Porreca, F., 1994. Naltrindole, an opioid delta antagonist, blocks the enhancement of morphine-antinociception induced by a CCKB antagonist in the rat. Neurosci. Lett. 181, 9-12.
36. Pournaghash, S., Riley, A.L., 1991. Failure of cholecystokinin to precipitate withdrawal in morphine-treated rats. Pharmacol. Biochem. Behav. 38, 479-484.
37. Rose, C., Vargas, F., Faochinetti, P., et al., 1996. Characterization and inhibition of a cholecystokinin-inactiving serine peptidase. Nature 380, 403-409.
38. Saelens, J.K., Granat, F.R., Sawyer, W.K., 1971. The mouse jumping test. A simple screening method to estimate the physical dependence capacity of analgesics. Arch. Int. Pharmacodyn. Ther. 190, 213-218.
39. Shen, K.F., Crain, S.M., 1992. Chronic selective activation of excitatory opioid receptor functions in sensory neurons results in opioid dependence without tolerance. Brain Res. 597, 74-83.
40. Stengaard-Pedersen, K., Larsson, L.I., 1981. Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system. Peptides 2, 3-19.
41. Taylor, J.R., Elsworth, J.D., Garcia, E.J., Grant, S.J., Roth, R.N., Redmond, Jr. D.E., 1988. Clonidine infusions into the locus coeruleus attenuate behavioral and neurochemical changes associated with naloxone-precipitated withdrawal. Psychopharmacology 96, 121-131.
42. Vasar, F., Maimets, M., Nurk, A., Soosaar, A., Allikmets, L., 1986. Comparison of motor depressant effects of caerulein and N-propylnorapomorphine. Pharmacol. Biochem. Behav. 24, 469-478.
43. Vasar, F., Harro, J., Pöld, A., Lang, A., 1992. CCK receptors and anxiety in rats. In: Dourish, C.T., Cooper, S.J., Iversen, S.D., Iversen, I.I. (Eds.), Multiple Cholecystokinin Receptors in CNS. Oxford University Press, New York, pp. 57-76.
44. Wennogle, L.P., Steel, D.J., Petrack, B., 1985. Characterization of central cholecystokinin receptors using a radioiodinated octapeptide probe. Life Sci. 36, 1485-1492.
45. Xu, X.J., Wiesenfeld-Hallin, Z., Hughes, D.C., Horwall, D.C., Hökfelt, T., 1992. CI 988, a selective antagonist of cholecystokinin B receptors prevents morphine tolerance in the rat. Br. J. Pharmacol. 105, 129-132.
46. Zabin, M.A., Innis, R.B., Warmsley, J.K., Snyder, S.H., Kuhar, M.J., 1983. Autoradiographic localization of cholecystokinin receptors in rodent brain. J. Neurosci. 3, 877-906.
47. Zetler, G., 1980. Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8). Neuropharmacology 19, 415-422.
48. Zetler, G., 1985. Caerulein and its analogues: neuropharmacological properties. Peptides 6 (suppl. 3), 33-46.